Oryzon Genomics SA (ORY) AI Stock Analysis

• Market Cap: €218.59M
• Dividend Yield: N/A
• Average Volume (3M): 533.99K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.56
• Revenue Growth: N/A
• EPS Growth: -36.82%
• Country: ES
• Employees: 47
• Sector: Healthcare
• Sector Strength: 59
• Industry: Biotechnology
• EPS (TTM): -0.03
• Shares Outstanding: 78,547,620
• 10 Day Avg. Volume: 541,451
• 30 Day Avg. Volume: 533,986
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €8.00
• Price Target Upside: 186.74% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 55 Neutral
• Price Target: €3.00 ▲(7.53%Upside)

Oryzon Genomics SA's score is primarily impacted by its financial performance and valuation. The company's high gross margins are overshadowed by consistent net losses and negative cash flows, while its valuation is unattractive due to the negative P/E ratio and lack of dividends. Technical analysis indicates a neutral market position, lacking strong momentum.

Oryzon Genomics SA Business Overview & Revenue Model

Company Description

Oryzon Genomics SA (ORY) is a clinical-stage biopharmaceutical company based in Spain, focused on developing innovative therapies in the field of epigenetics. The company specializes in discovering and developing small molecule inhibitors for the treatment of diseases with unmet medical needs, particularly in oncology and neurodegenerative disorders. Oryzon's leading drug candidates include iadademstat and vafidemstat, which are under various stages of clinical development.

How the Company Makes Money

Oryzon Genomics SA primarily generates revenue through collaborative research and development agreements, milestone payments, and licensing deals with other pharmaceutical companies and research institutions. These partnerships often involve joint efforts in drug discovery and development, leveraging Oryzon's expertise in epigenetics to create novel therapeutics. The company also aims to earn revenue from future product sales upon successful clinical trials and regulatory approvals of its drug candidates. Additionally, Oryzon may receive funding from grants and public or private sector contributions to support its research and development activities.

Oryzon Genomics SA Financial Statement Overview

Summary

Oryzon Genomics SA demonstrates strong gross profit margins but is hindered by consistent net losses and negative cash flows. The company has a solid equity position, though increasing debt is a concern. Overall, financial health is unstable due to the lack of profitability.

Income Statement

Oryzon Genomics SA shows improving revenue presence with a significant increase from zero in 2020 to 2024, however, revenue has declined in the past year. Gross profit margins are high, but the company is operating at a net loss, impacting the net profit margin and EBIT/EBITDA margins negatively. The company appears to be focusing on growth and development, typical for the biotechnology sector, yet consistent losses are a concern.

Balance Sheet

The balance sheet indicates a strong equity position with a high equity ratio, suggesting stability. However, the debt-to-equity ratio has increased slightly, indicating rising leverage. Return on equity is currently negative due to ongoing losses. Overall, the company maintains a solid asset base, but increasing debt levels should be monitored.

Cash Flow

Cash flows reveal consistent negative free cash flow, reflecting heavy investment and operating cash outflows. The operating cash flow to net income ratio is negative due to losses. Financing activities are positive, suggesting reliance on external funding. Continuous negative cash flow is a risk, but typical for growth-focused biotech firms.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
7.36M	14.19M	15.70M	10.62M	9.52M
	Gross Profit
7.06M	13.95M	15.23M	9.87M	8.99M
	EBIT
-4.42M	-4.55M	-5.49M	-7.01M	-4.29M
	EBITDA
-4.43M	-4.26M	-5.08M	-6.88M	-4.16M
	Net Income Common Stockholders
-3.67M	-3.35M	-4.23M	-4.69M	-3.40M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
5.62M	12.26M	21.32M	28.72M	39.60M
	Total Assets
108.72M	106.90M	103.70M	95.38M	94.11M
	Total Debt
16.21M	13.69M	17.44M	13.77M	9.09M
	Net Debt
10.59M	1.43M	-3.88M	-14.95M	-30.51M
	Total Liabilities
21.67M	25.13M	31.13M	24.12M	18.18M
	Stockholders Equity
87.04M	81.77M	72.57M	71.26M	75.93M
Cash Flow		Free Cash Flow
-5.69M	-15.08M	-16.12M	-15.39M	-14.04M
	Operating Cash Flow
-5.69M	-574.96K	-1.85M	-3.63M	-4.82M
	Investing Cash Flow
-7.81M	-14.50M	-14.27M	-11.72M	-9.08M
	Financing Cash Flow
6.87M	6.02M	8.71M	4.12M	18.38M

Oryzon Genomics SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.79
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:ORY, the sentiment is Positive. The current price of 2.79 is above the 20-day moving average (MA) of 2.77, above the 50-day MA of 2.74, and above the 200-day MA of 2.12, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 50.85 is Neutral, neither overbought nor oversold. The STOCH value of 42.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:ORY.

Oryzon Genomics SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ROVI	78 Outperform	€2.88B	20.54	25.24%	1.59%	-1.49%	4.04%
RJF	75 Outperform	€253.10M	23.08	5.11%	1.28%	5.10%	20.61%
PHM	61 Neutral	$1.50B	73.24	10.15%	0.72%	8.39%	947.08%
ORY	55 Neutral	€218.59M	―	-5.48%	―	―	-36.82%
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
ATRY	44 Neutral	€208.18M	―	-11.64%	―	5.54%	30.33%

Oryzon Genomics SA Corporate Events

Oryzon Genomics Announces 2025 Shareholders Meeting

Oryzon Genomics SA has announced the convening of its Ordinary General Meeting of Shareholders, scheduled for June 27, 2025, in Madrid. The meeting will address several key agenda items, including the approval of the annual accounts and management report for the fiscal year ending December 31, 2024, and the application of the fiscal year’s results. This meeting is significant for stakeholders as it will cover crucial financial and operational decisions that could impact the company’s strategic direction and shareholder interests.

The most recent analyst rating on (ES:ORY) stock is a Buy with a EUR2.30 price target. To see the full list of analyst forecasts on Oryzon Genomics SA stock, see the ES:ORY Stock Forecast page.

Oryzon Genomics Strengthens Financial Position and Advances Clinical Trials in Q1 2025

Oryzon Genomics reported a net loss of €1.7M for Q1 2025, aligning with its long-term product development strategy. The company strengthened its financial position with a €30M capital increase and is preparing for a Phase III trial of vafidemstat for Borderline Personality Disorder. Additionally, Oryzon is advancing its oncology trials and expects a significant grant to boost its therapeutic development programs.

Oryzon Genomics Secures €13.26 Million for VANDAM Project under IPCEI

Oryzon Genomics S.A. has been granted a non-refundable aid of approximately €13.26 million from the Med4Cure project, the first Important Project of Common European Interest (IPCEI) in the healthcare sector. This funding will support the VANDAM project, covering 64% of its total budget, and will enable Oryzon to accelerate the clinical development of its epigenetic agents, vafidemstat and iadademstat, for treating rare diseases and hard-to-treat cancers, thereby strengthening its financial position and enhancing its mental health program.

Oryzon Genomics Announces €25 Million Capital Increase for Clinical Expansion

Oryzon Genomics SA has announced a capital increase of 25 million euros through an accelerated private placement to institutional investors. The proceeds will be used to expand clinical development in CNS diseases and oncology, prepare for Phase IIb-III trials, strengthen the balance sheet for potential partnerships, and explore a dual listing on Nasdaq.

Oryzon Genomics Announces €25 Million Capital Increase for Clinical Expansion

Oryzon Genomics SA has announced a capital increase of 25 million euros through an accelerated private placement of ordinary shares. The funds will be used to enhance clinical development in CNS diseases and oncology, prepare for drug manufacturing, and strengthen the balance sheet for potential partnerships and Nasdaq listing.

Oryzon Genomics Announces €25 Million Capital Increase for Clinical Expansion

Oryzon Genomics SA has announced a capital increase of 25 million euros through an accelerated private placement to institutional investors. The funds will be used to advance clinical development in CNS diseases and oncology, prepare for Phase IIb-III trials, and strengthen its financial position for potential partnerships or Nasdaq listing.